About Us: Leadership
Although Topo Medtech is a startup company, it has a rich history. Prior to forming Topo Medtech, Zhisong Cao was principally responsible for CPT drug development at the Christus Stehlin Foundation for Cancer Research. Zhisong was at the forefront of CPT drug development and amassed over twenty years of experience working with and developing these compounds. This experience and intimate acquired knowledge of CPT drugs rivals and may even surpass those of much larger companies. With this knowledge he feels he now has the keys to unlocking the full potential of "Taking natures best anti-cancer compound and making man's best cancer drugs".
Zhisong Cao, Ph.D., CEO and Chief Chemist: Over twenty years of experience in CPT chemistry, inventor and co-holder of 17 CPT related patents, and licensing of CPT compounds. Prior to co-founding Topo Medtech, he served as the Associate Laboratory Director and Chief Chemist for the Stehlin Foundation. In this capacity he was responsible for all Chemistry R&D, and strategic direction of drug development, patenting and licensing. In his twenty years of being solely involved in CPT drugs, he has synthesized hundreds of CPT drugs using thousands of drug intermediates. This enormous amount of knowledge provides Topo Medtech a distinct advantage in the design and synthesis of these drugs targeted for specific pharmacological activity.